Radicut (edaravone) — FDA approved under the brand name Radicava

€992.00
In stock
SKU
Radicut (edaravone) — FDA approved under the brand name Radicava

Please note that we have a generic form of edaravone (made by Pfizer and other brands) available to order as well. [Edaravone]. 

Radicut (edaravone) is a medication for the treatment of patients with amyotrophic lateral sclerosis (ALS) and acute ischaemic stroke.

How to buy Radicut: you can order Radicut (edaravone) via TheSocialMedwork if the drug has not been approved or is not available in the patients country. 

Neurology Amyotrophic Lateral Sclerosis (ALS), Cerebral Infarction
Marketing Authorisation Holder Mitsubishi Tanabe Pharma Co., Ltd.
Mode of Action Radical scavenger
Administration Intravenous
Regulatory agency approval Food and Drug Administration (FDA), USA, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

What is Radicut (edaravone) for?

Radicut (edaravone) is a radical scavenger used to treat patients with ALS1,8 or ischaemic stroke1

Radicut (edaravone) is approved in Japan under the name Radicut for both indications2 and in the USA under the name Radicava for the treatment of ALS7. Radicava and Radicut contain the same active ingredient edaravone.

How does Radicut (edaravone) work?

Free radicals such as hydroxyl radical (-OH) play a major causative role in the development of cerebral vascular disorder resulting from ischaemia. During ischaemia or ischaemic reperfusion, the production of free radicals increases which leads to cell membrane injury and ultimately to cerebral dysfunction1.

Although the etiology of development and disease progress of amyotrophic lateral sclerosis (ALS) are unknown, a possible involvement of oxidative stress caused by free radicals is suggested1.
The mechanism by which edaravone exerts its therapeutic effect in patients with ALS is unknown8. It is expected that edaravone scavenges free radicals and prevents oxidative damage to brain cells (vascular endothelial cells/nerve cells). In the case of amyotrophic lateral sclerosis (ALS), this product is expected to suppress the disease progression by exerting its inhibitory effects against the development of oxidative damage to nerve cells1.

Where has Radicut (edaravone) been approved?

Radicut (edaravone) was approved by:

  • PMDA (JAP) as Radicut:
    • in June 2001 for acute ischemic stroke2
    • in June 2015 for the treatment of ALS2.
  • FDA (USA) on May 5, 2017, as Radicava for the treatment of ALS7.

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Radicut (edaravone) taken?

The standard dosage for adult patients affected by disorders associated with ischaemic stroke is1:

  • 30 mg of edaravone diluted with an appropriate volume of physiological saline, etc., which is administered intravenously over 30 minutes twice a day in the morning and the evening.

Administration of this product should be initiated within 24 hours after the onset of the disease, and the duration of administration should be within 14 days.

The standard dosage for adult patients with ALS is1,8:

  • 60 mg of edaravone administered intravenously over 60 minutes once a day.
  • First cycle: daily dosing for 14 days followed by a 14-day drug-free period
  • Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods.

Radicut, distributed by MT Pharma Japan, is supplied in two formats1:

  • Single-dose infusion bags containing 30 mg / 100 mL clear, colorless, sterile solution. The infusion bags are ready for use. No dilution is required. Two infusion bags are needed for one infusion.
  • Single-dose vials containing 30 mg / 20 mL clear, colorless, sterile solution. Before the infusion, it should be diluted with an appropriate volume of physiological saline. Two vials are needed for one infusion.

Radicava, distributed by MT Pharma America, Inc, is supplied in single-dose polypropylene bags containing 30 mg/100 mL clear, colourless, sterile solution for intravenous infusion (no dilution needed). Each 60 mg dose should be administered as two consecutive 30 mg intravenous infusion bags over a total of 60 minutes (infusion rate approximately 1 mg per minute)8.

Complete information about Radicut (edaravone) dosage and administration can be found for Radicut1 (with an unofficial translation10) and for Radicavain our resources section.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known side effects of Radicut (edaravone)?

The most common side effects reported by clinical trial participants receiving edaravone were bruising (contusion) and gait disturbance. It is also associated with serious risks that require immediate medical care, such as hives, swelling, or shortness of breath, and allergic reactions to sodium bisulfite, an ingredient in the drug7.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,8.

More Information
Working ingredient edaravone
Shipping method Standard (not temperature controlled)
Therapeutic Area Neurology
Neurology Amyotrophic Lateral Sclerosis (ALS), Cerebral Infarction
Indication Amyotrophic Lateral Sclerosis (ALS)
Indication Neurological symptoms, disability in daily living, and functional impairment accompanying the acute phase of cerebral infarction
Administration Intravenous
Mode of Action Radical scavenger
Regulatory agency approval Food and Drug Administration (FDA), USA, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Marketing Authorisation Holder Mitsubishi Tanabe Pharma Co., Ltd.
Distributor MT Pharma Japan
HS Code N/A
CAS Number N/A

The approval for the treatment of ALS was based on a study (MCI186-19) which compared the effect of edaravone with placebo on 137 ALS patients (69 patients on edaravone; 68 patients on placebo). The study consisted of 6 cycles. The comparison was based on the changes in the ALSFRS-R scores before and after the treatment. The ALSFRS-R scale consists of 12 questions that evaluate the fine motor, gross motor, bulbar, and respiratory function of patients with ALS in activities as speech, salivation, swallowing, handwriting, cutting food, dressing/hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item is scored from 0-4, with higher scores representing greater functional ability8. Although rates of ALS progression can vary significantly, research shows that people with ALS lose an average of one point per month on the ALSFRS-R scale9. The patients selected for the study had ALSFRS-R scores of minimum 2 on all 12 items; normal respiratory function (defined as percent-predicted forced vital capacity values of [% FVC] ≥80 %); disease duration of maximum 2 years. The majority of patients (90%) in both groups were treated during the course of the study with another medicine named riluzole8.

The decline in ALSFRS-R scores from baseline after 24 weeks was significantly less in the edaravone-treated patients (Mean ± Standard Error (95 % CI) = - 5.01 ± 0.64) as compared to placebo (Mean ± Standard Error (95 % CI) = - 7.50 ± 0.66) with a difference between edaravone and placebo on the ALSFRS-R scale of 2.49 (95 % CI = 0.99, 3.98)8. This corresponds to a 33 % difference between the two groups9.

As it is the case with every medicine, the effect of edaravone, although on average superior to placebo, was not the same for all patients8.

Additional results can be found in our resources section1,3,4.

In December 2014, edaravone was granted orphan designation by the European Commission for the treatment of ALS5. The European Medicine Agency (EMA) granted the orphan designation6 based on the following expected mechanism of action:

"Damage to nerve cells in ALS appears to have several causes but there is evidence that it may involve damage to nerves caused by toxic molecules containing oxygen. In some patients, this is associated with a defect in the gene responsible for producing the enzyme called superoxide dismutase (SOD), which causes the enzyme to clump together inside nerve cells. This leads to inflammation and kills the affected nerve cells. Edaravone is expected to act as an antioxidant, a molecule that can prevent damage to nerve cells caused by oxygen-containing molecules, and also blocks the clumping together of SOD in the nerves and so reduces inflammation..."

1. Summary of Product Characteristics [PMDA]: Radicut (edaravone) [PDF]
Mitsubishi Tanabe Pharma Corporation, June 2015.

2. MT Pharma Press Release. MT Pharma Co. receives approval for additional indication for ALS in Japan.
26/06/2015.

3. Abe K., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec; 15(7–8):610–7

4. Yoshino H. and Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
Amyotroph Lateral Scler. 2006 Dec.; 7(4):241–5.

5. EMA. Public summary of opinion on orphan designation. [PDF]
23/02/2015.

6. EMA. Orphan Designation.
Cited on Jun. 2016.

7. FDA News Release: FDA approves drug to treat ALS,
05/05/2017.

8. Summary of Product Characteristics [FDA]: Radicava (edaravone) [PDF] 
MT Pharma America Inc., May 2017.

9. Multivu.com. What is Radicava (edaravone)?
Cited on May 2017.

https://www.multivu.com/players/English/8047051-mt-pharma-america-radicava-fda-approval/docs/radicavaproductfs-1494020153658-192439555.pdf 

10. Summary of Product Characteristics [Unofficial translation]: Radicut (edaravone),
Jun. 2015. 

http://www.e-search.ne.jp/~jpr/PDF/MT18.PDF

Shipping Type Standard
Shipping method Standard (not temperature controlled)
Dynamic Weight No
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

How can we help you?

We're ready to answer any question!

Our Support team is available between
9:00–18:00 Central European Time, Monday to Friday.

 

Don't speak English? We also speak
Afrikaans, Armenian, Bosnian, Bulgarian, Dutch, French, German, Italian, Lithuanian, Mandarin, Polish, Portuguese, Russian, Serbian, Slovenian, Spanish and Turkish

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 


Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.